Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced that on May 6, 2022 (local time), its consolidated subsidiary, Myovant Sciences Ltd. (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis as per the attachment.

The update on the sNDA for MYFEMBREE does not affect its consolidated financial results of the fiscal year ended March 2022. The impact of this matter on its consolidated financial results of the fiscal year ending March 2023 will be announced as soon as it becomes clear.

Contact:

TEL: [phone]

Osaka

T: [phone]

Tokyo

(C) 2022 Electronic News Publishing, source ENP Newswire